HarperCollins e-books电子书

售价：¥

2人正在读 | 0人评论

9.8

作者：Prud'homme, Alex

出版社：HarperCollins e-books

出版时间：2009-10-01

字数：74.9万

所属分类：进口书 > 外文原版书 > 经管/金融

温馨提示：数字商品不支持退换货，不提供源文件，不支持导出打印

为你推荐

Team Management (Collins Business Secrets)

￥18.74

Finance Basics (Collins Business Secrets)

￥22.76

Communication (Collins Business Secrets)

￥51.50

Money Never Enough:Learn to Unlearn to Relearn the New Economy

￥30.88
Pitch Perfect

￥155.02

Negotiation Skills in 7 simple steps

￥61.51

Get that Job in 7 simple steps

￥61.51

People Management (Collins Business Secrets)

￥44.24

读书简介
目录
累计评论(0条)

读书简介
目录
累计评论(0条)

"It began with a promising cancer drug, the brainchild of a gifted researcher, and grew into an insider trading scandal that ensnared one of America's most successful women. The story of ImClone Systems and its "miracle" cancer drug, Erbitux, is the quintessential business saga of the late 1990s. It's the story of big money and cutting-edgescience, celebrity, greed, and slipshod business practices; the story of biotech hype and hope and every kind of excess.At the center of it all stands a single, enigmatic figure named Sam Waksal. A brilliant, mercurial, and desperate-to-be-liked entrepreneur, Waksal was addicted to the trappings of wealth and fame that accrued to a darling of the stock market and the overheated atmosphere of biotech IPOs. At the height of his stardom, Waksal hobnobbed with Martha Stewart in New York and Carl Icahn in the Hamptons, hosted parties at his fabulous art-filled loft, and was a fixture in the gossip columns. He promised that Erbitux would "change oncology," and would soon be making $1 billion a year.But as Waksal partied late into the night, desperate cancer patients languished, waiting for his drug to come to market. When the FDA withheld approval of Erbitux, the charming scientist who had always stayed just one step ahead of bankruptcy panicked and desperately tried to cash in his stock before the bad news hit Wall Street.Waksal is now in jail, the first of the Enron-era white-collar criminals to be sentenced. Yet his cancer drug has proved more durable than his evanescent profits. Erbitux remains promising, the leading example of a new way to fight cancer, and patients and investors hope it will be available soon.

目录展开